CITIUS ONCOLOGY, INC. - 8-K Filing
Citius Oncology reported $1.7 million in net product revenue for Q2 fiscal 2026, with a gross margin of approximately 80%, and $5.6 million in total six-month revenue as LYMPHIR's launch progressed. The company secured up to $36.5 million in financing post-quarter end through a $25 million term loan from Avenue Capital Group and $11.5 million from warrant exercises, bringing cash reserves to $2.6 million by March 31, 2026. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $CTOR